Pemetrexed induces S-phase arrest and apoptosis via a deregulated activation of Akt signaling pathway

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Chen, Kun Chieh ^a,b   Yang, Tsung Ying ^a   Wu, Chun Chi ^c,d   Cheng, Chi Chih ^a   Hsu, Shih Lan ^a,b,d   Hung, Hsiao Wen ^a   Chen, Jian Wei ^b   Chang, Gee Chen ^a,b,e  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE 2; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYCLIN A; CYCLIN-DEPENDENT KINASE 2; ENZYME ACTIVATION; GLUTAMATES; GUANINE; HUMANS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; S PHASE CELL CYCLE CHECKPOINTS; SIGNAL TRANSDUCTION;

EID: 84901365244     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097888     Document Type: Article

References (60)

1. Lee YC, Wu CT, Chen CS, Hsu HH, Chang YL (2002) The significance of E-cadherin and alpha-, beta-, and gamma-catenin expression in surgically treated non-small cell lung cancers of 3 cm or less in size. J Thorac Cardiovasc Surg 123: 502-507.
2. Wakelee H, Belani CP (2005) Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 10 Suppl 3: 1-10. (Pubitemid 43152725)
3. Ramalingam S, Belani C (2008) Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13 Suppl 1: 5-13.
4. Edelman MJ, Le Chevalier T, Soria JC (2012) Maintenance therapy and advanced non-small-cell lung cancer: a skeptic's view. J Thorac Oncol 7: 1331-1336.
5. Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, et al. (2010) Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14: 33-39.
6. Gonen N, Assaraf YG (2012) Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat 15: 183-210.
7. Britten CD, Izbicka E, Hilsenbeck S, Lawrence R, Davidson K, et al. (1999) Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother Pharmacol 44: 105-110. (Pubitemid 29297055)
8. Teicher BA, Alvarez E, Liu P, Lu K, Menon K, et al. (1999) MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin Oncol 26: 55-62.
9. Teicher BA, Chen V, Shih C, Menon K, Forler PA, et al. (2000) Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 6: 1016-1023. (Pubitemid 30159362)
10. Vadlakonda L, Dash A, Pasupuleti M, Anil Kumar K, Reddanna P (2013) The Paradox of Akt-mTOR Interactions. Front Oncol 3: 165.
11. Vadlakonda L, Pasupuleti M, Pallu R (2013) Role of PI3K-AKT-mTOR and Wnt Signaling Pathways in Transition of G1-S Phase of Cell Cycle in Cancer Cells. Front Oncol 3: 85.
12. Welker ME, Kulik G (2013) Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors. Bioorg Med Chem 21: 4063-4091.
13. Ma X, Hu Y (2013) Targeting PI3K/Akt/mTOR cascade: the medicinal potential, updated research highlights and challenges ahead. Curr Med Chem 20: 2991-3010.
14. Khan KH, Yap TA, Yan L, Cunningham D (2013) Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer 32: 253-265.
15. Aki T, Yamaguchi K, Fujimiya T, Mizukami Y (2003) Phosphoinositide 3-kinase accelerates autophagic cell death during glucose deprivation in the rat cardiomyocyte-derived cell line H9c2. Oncogene 22: 8529-8535. (Pubitemid 37523905)
16. Lu B, Wang L, Stehlik C, Medan D, Huang C, et al. (2006) Phosphatidylinositol 3-kinase/Akt positively regulates Fas (CD95)-mediated apoptosis in epidermal Cl41 cells. J Immunol 176: 6785-6793. (Pubitemid 43787861)
17. Nimbalkar D, Henry MK, Quelle FW (2003) Cytokine activation of phosphoinositide 3-kinase sensitizes hematopoietic cells to cisplatin-induced death. Cancer Res 63: 1034-1039. (Pubitemid 36278435)
18. Shack S, Wang XT, Kokkonen GC, Gorospe M, Longo DL, et al. (2003) Caveolin-induced activation of the phosphatidylinositol 3-kinase/Akt pathway increases arsenite cytotoxicity. Mol Cell Biol 23: 2407-2414. (Pubitemid 36351022)
19. Narayan RS, Fedrigo CA, Stalpers LJ, Baumert BG, Sminia P (2013) Targeting the Akt-pathway to improve radiosensitivity in glioblastoma. Curr Pharm Des 19: 951-957.
20. Li T, Ling YH, Goldman ID, Perez-Soler R (2007) Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 13: 3413-3422. (Pubitemid 46944930)
21. Yang TY, Chang GC, Chen KC, Hung HW, Hsu KH, et al. (2011) Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells. Eur J Pharmacol 663: 17-26.
22. Yang TY, Chang GC, Chen KC, Hung HW, Hsu KH, et al. (2013) Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways. Mol Carcinog 52: 183-194.
23. Liang J, Slingerland JM (2003) Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2: 339-345.
24. Tekle C, Giovannetti E, Sigmond J, Graff JR, Smid K, et al. (2008) Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer 99: 750-759.
25. Stiles BL (2009) PI-3-K and AKT: Onto the mitochondria. Adv Drug Deliv Rev 61: 1276-1282.
26. van Gorp AG, Pomeranz KM, Birkenkamp KU, Hui RC, Lam EW, et al. (2006) Chronic protein kinase B (PKB/c-akt) activation leads to apoptosis induced by oxidative stress-mediated Foxo3a transcriptional up-regulation. Cancer Res 66: 10760-10769. (Pubitemid 44876971)
27. Maddika S, Panigrahi S, Wiechec E, Wesselborg S, Fischer U, et al. (2009) Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin's anticancer toxicity. Mol Cell Biol 29: 1235-1248.
28. Maddika S, Ande SR, Wiechec E, Hansen LL, Wesselborg S, et al. (2008) Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. J Cell Sci 121: 979-988. (Pubitemid 351639417)
29. Welsh SJ, Titley J, Brunton L, Valenti M, Monaghan P, et al. (2000) Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues. Clin Cancer Res 6: 2538-2546. (Pubitemid 30399226)
30. Tonkinson JL, Marder P, Andis SL, Schultz RM, Gossett LS, et al. (1997) Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 39: 521-531. (Pubitemid 27096768)
31. Jackson RC (1984) Biological effects of folic acid antagonists with antineoplastic activity. Pharmacol Ther 25: 61-82.
32. Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG (1999) Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 59: 3671-3676. (Pubitemid 29381871)
33. Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, et al. (2011) Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 104: 1594-1601.
34. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
35. Alvarez B, Martinez AC, Burgering BM, Carrera AC (2001) Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature 413: 744-747. (Pubitemid 33009953)
36. Bischof M, Abdollahi A, Gong P, Stoffregen C, Lipson KE, et al. (2004) Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. Int J Radiat Oncol Biol Phys 60: 1220-1232. (Pubitemid 39440809)
37. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, et al. (2005) Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68: 110-118. (Pubitemid 41002949)
38. Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, et al. (2011) Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br J Cancer 105: 1542-1553.
39. Grana X, Reddy EP (1995) Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11: 211-219.
40. Huang X, Summers MK, Pham V, Lill JR, Liu J, et al. (2011) Deubiquitinase USP37 is activated by CDK2 to antagonize APC(CDH1) and promote S phase entry. Mol Cell 42: 511-523.
41. Neganova I, Vilella F, Atkinson SP, Lloret M, Passos JF, et al. (2011) An important role for CDK2 in G1 to S checkpoint activation and DNA damage response in human embryonic stem cells. Stem Cells 29: 651-659.
42. Yam CH, Fung TK, Poon RY (2002) Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 59: 1317-1326.
43. Volm M, Rittgen W, Drings P (1998) Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 77: 663-669. (Pubitemid 28059477)
44. Adachi S, Ito H, Tamamori-Adachi M, Ono Y, Nozato T, et al. (2001) Cyclin A/cdk2 activation is involved in hypoxia-induced apoptosis in cardiomyocytes. Circ Res 88: 408-414. (Pubitemid 32200114)
45. Ding H, Han C, Guo D, Wang D, Chen CS, et al. (2008) OSU03012 activates Erk1/2 and Cdks leading to the accumulation of cells in the S-phase and apoptosis. Int J Cancer 123: 2923-2930.
46. Zhan Z, He K, Zhu D, Jiang D, Huang YH, et al. (2012) Phosphorylation of Rad9 at serine 328 by cyclin A-Cdk2 triggers apoptosis via interfering Bcl-xL. PLoS One 7: e44923.
47. Jin YH, Yoo KJ, Lee YH, Lee SK (2000) Caspase 3-mediated cleavage of p21WAF1/CIP1 associated with the cyclin A-cyclin-dependent kinase 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells. J Biol Chem 275: 30256-30263.
48. Jin YH, Yim H, Park JH, Lee SK (2003) Cdk2 activity is associated with depolarization of mitochondrial membrane potential during apoptosis. Biochem Biophys Res Commun 305: 974-980. (Pubitemid 36597859)
49. Choi JS, Shin S, Jin YH, Yim H, Koo KT, et al. (2007) Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis. Apoptosis 12: 1229-1241. (Pubitemid 46890378)
50. Eapen AK, Henry MK, Quelle DE, Quelle FW (2001) Dna damage-induced G(1) arrest in hematopoietic cells is overridden following phosphatidylinositol 3-kinase-dependent activation of cyclin-dependent kinase 2. Mol Cell Biol 21: 6113-6121. (Pubitemid 34263511)
51. Yoshida K, Wang HG, Miki Y, Kufe D (2003) Protein kinase Cdelta is responsible for constitutive and DNA damage-induced phosphorylation of Rad9. EMBO J 22: 1431-1441. (Pubitemid 36362706)
52. Eitel K, Staiger H, Rieger J, Mischak H, Brandhorst H, et al. (2003) Protein kinase C delta activation and translocation to the nucleus are required for fatty acid-induced apoptosis of insulin-secreting cells. Diabetes 52: 991-997. (Pubitemid 36384269)
53. DeVries-Seimon TA, Ohm AM, Humphries MJ, Reyland ME (2007) Induction of apoptosis is driven by nuclear retention of protein kinase C delta. J Biol Chem 282: 22307-22314. (Pubitemid 47267361)
54. Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K (2007) DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell 25: 725-738. (Pubitemid 46341924)
55. Yoshida K, Yamaguchi T, Natsume T, Kufe D, Miki Y (2005) JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage. Nat Cell Biol 7: 278-285. (Pubitemid 40331129)
56. Raina D, Ahmad R, Kumar S, Ren J, Yoshida K, et al. (2006) MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J 25: 3774-3783. (Pubitemid 44300263)
57. Maddika S, Bay GH, Kroczak TJ, Ande SR, Maddika S, et al. (2007) Akt is transferred to the nucleus of cells treated with apoptin, and it participates in apoptin-induced cell death. Cell Prolif 40: 835-848. (Pubitemid 350135205)
58. Dai Y, Grant S (2003) Cyclin-dependent kinase inhibitors. Curr Opin Pharmacol 3: 362-370. (Pubitemid 36908939)
59. Schuurbiers OC, Kaanders JH, van der Heijden HF, Dekhuijzen RP, Oyen WJ, et al. (2009) The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 4: 761-767.
60. Gadgeel SM, Wozniak A (2013) Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clin Lung Cancer 14: 322-332.